GC 1102

Drug Profile

GC 1102

Alternative Names: GC-1102; HepaBig Gene - Green Cross

Latest Information Update: 03 Mar 2017

Price : $50

At a glance

  • Originator Green Cross
  • Class Antivirals; Monoclonal antibodies; Recombinant proteins
  • Mechanism of Action Viral antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Hepatitis B

Most Recent Events

  • 03 Mar 2017 Phase-II development is ongoing in South Korea (IV)
  • 01 May 2016 Green Cross Corporation completes a phase I trial for chronic Hepatitis B in South Korea (NCT02569372)
  • 01 Feb 2015 Phase-II clinical trials in Hepatitis B (Prevention) in South Korea (IV) (NCT02304315)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top